Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Guardant Health Inc.
Headquarters: Palo Alto, CA, United States of America
Website: http://www.guardanthealth.com...
Year Founded: 2012
Status: Public
Industry Sector: HealthServices
CEO: Helmy Eltoukhy, PhD; AmirAli H. Talasaz, PhD
Number Of Employees: 2,021
Enterprise Value: $4,245,933,750
PE Ratio: -11.82
Exchange/Ticker 1: NASDAQ:GH
Exchange/Ticker 2: N/A
Latest Market Cap: $5,367,579,136
BioCentury | Feb 24, 2024
Management Tracks
Petroutsas to lead U.S. commercial operations at Astellas
Plus: Evan Ballantyne named CFO at Hansa and updates from BostonGene and InflaRx
BioCentury | Jun 8, 2023
Data Byte
May brings year’s strongest follow-on activity to date
18 biopharmas raised $2.2B, with Guardant and ImmunoGen each raising over $300M
BioCentury | May 9, 2023
Management Tracks
Hofmann named CEO at Vicinitas
Plus: New COO, CTO at Guardant, Scangos joins Voyager’s board, and updates from Mariana, Merck KGaA, CymaBay and more
BioCentury | Feb 11, 2023
Emerging Company Profile
Haystack: personalized liquid biopsy tests for minimal residual disease
Baltimore biotech readies to launch colon cancer monitoring test, funded by $56M series A led by co-founder Catalio
BioCentury | Jan 28, 2023
Regulation
Jan. 27 Quick Takes: FDA approves first oral SERD
Plus: FDA approves Jaypirca, Lilly’s non-covalent Btk inhibitor and updates from Novartis, Legend, Goldfinch Bio and Relive
BioCentury | Jan 13, 2023
Finance
4Q22 Wrap: Stopping the bleeding
Winners, losers across biotech market cap tiers in 4Q22
BioCentury | Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Sep 1, 2022
Management Tracks
Demuth to lead R&D at MorphoSys as Peters retires
Plus new CFO, CBO, general counsel at Revolution, and updates from Photocure, Nature’s Toolbox, Ginkgo and more
BioCentury | Aug 12, 2022
Finance
Aug. 11 Quick Takes: Verona, CinCor raise cash on heels of data readouts
Plus Enhertu wins lung cancer approval and updates from GSK, Novartis, argenx and more
BioCentury | Jul 18, 2022
Emerging Company Profile
Delfi: Making early cancer detection tests more accessible
Diagnostic company aims for early 2023 early cancer detection test launch with $225M B round
Items per page:
1 - 10 of 76